Lista de obras -

Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals.

artículo científico publicado en 2016

Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series

scientific article published on 26 October 2012

Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma

artículo científico publicado en 2022

Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors

scientific article published on 25 May 2019

Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study

artículo científico publicado en 2016

Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis

artículo científico publicado en 2020

French national survey on incoming phone calls in oncology departments

artículo científico publicado en 2017

GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma.

artículo científico publicado en 2011

Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges

scientific article published on 27 November 2017

Immune checkpoint inhibitors myocarditis: not all cases are clinically patent

scientific article published on 01 October 2018

Immune-based identification of cancer patients at high risk of progression

artículo científico publicado en 2018

Immunothérapie dans les cancers de la prostate.

artículo científico publicado en 2016

Immunothérapie des cancers du rein

scientific article published on 01 December 2018

Molecular Classification of Renal Cell Carcinoma and Its Implication in Future Clinical Practice

artículo científico publicado en 2017

Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2.

artículo científico publicado en 2014

Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients

artículo científico publicado en 2018

Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma.

artículo científico publicado en 2014

PD-L1 Expression and CD8(+) T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer

artículo científico publicado en 2017

Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma

artículo científico publicado en 2017

Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC).

artículo científico publicado en 2015

Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents

artículo científico publicado en 2014

Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.

artículo científico

Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.

artículo científico publicado en 2017

Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma

artículo científico publicado en 2019

Sunitinib in kidney cancer: 10 years of experience and development.

artículo científico publicado en 2016

The clinical role of the TME in solid cancer

scientific article published on 09 November 2018

The role of rechallenge with targeted therapies in metastatic renal-cell carcinoma.

artículo científico

Tim-3: a novel biomarker and therapeutic target in oncology

artículo científico publicado en 2018

Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies.

artículo científico publicado en 2017

Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth

scientific article published on 04 June 2019

Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.

artículo científico publicado en 2017

Update on the most promising biomarkers of response to immune checkpoint inhibitors in clear cell renal cell carcinoma

artículo científico publicado en 2021

[Treatment of metastatic prostate cancer: what recent progress?]

scientific article published on 01 September 2018

Lista de obras de

Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals.

Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series

Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma

Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors

Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study

Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis

French national survey on incoming phone calls in oncology departments

GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma.

Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges

Immune checkpoint inhibitors myocarditis: not all cases are clinically patent

Immune-based identification of cancer patients at high risk of progression

Immunothérapie dans les cancers de la prostate.

Immunothérapie des cancers du rein

Molecular Classification of Renal Cell Carcinoma and Its Implication in Future Clinical Practice

Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2.

Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients

Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma.

PD-L1 Expression and CD8(+) T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer

Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma

Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC).

Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents

Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.

Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.

Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma

Sunitinib in kidney cancer: 10 years of experience and development.

The clinical role of the TME in solid cancer

The role of rechallenge with targeted therapies in metastatic renal-cell carcinoma.

Tim-3: a novel biomarker and therapeutic target in oncology

Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies.

Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth

Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.

Update on the most promising biomarkers of response to immune checkpoint inhibitors in clear cell renal cell carcinoma

[Treatment of metastatic prostate cancer: what recent progress?]